Consensus Adaptive Biotechnologies Corporation

Equities

ADPT

US00650F1093

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
2.51 ^USD	+4.58%		-13.75%	-48.78%

Apr. 05	Adaptive Biotechnologies Corporation Announces Preliminary Unaudited Revenue Results for the First Quarter Ended March 31, 2024	CI
Apr. 03	Adaptive Biotechnologies Corporation Announces CFO Changes	CI

Evolution of the average Target Price on Adaptive Biotechnologies Corporation

Price target over the last 5 years

History of analyst recommendation changes

5a3839d9a12.Sgl4eHboba_K3csu35-x_FycjSzSW5sYYH72wr6v5xs.B2MPLSOQHd2vrIJfgM_-nSTf6G-cI8hWChjPlPb23kEPTiI3Jo0r96ufmg~baaf4766ea1f76f76159c31695b48f50

Analyst Recommendations on Adaptive Biotechnologies Corporation

JPMorgan Adjusts Price Target on Adaptive Biotechnologies to $8 From $11, Maintains Overweight Rating	Feb. 15	MT
Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating	23-10-24	MT
BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating	23-10-20	MT
Morgan Stanley Trims Adaptive Biotechnologies' Price Target to $15 From $16, Maintains Equalweight Rating	23-02-16	MT
Scotiabank Initiates Adaptive Biotechnologies at Sector Outperform Rating With $15 Price Target	23-01-05	MT
Scotiabank Initiates Adaptive Biotechnologies at Sector Outperform With $15 Price Target	23-01-05	MT
Piper Sandler Upgrades Adaptive Biotechnologies to Overweight From Neutral, Adjusts Price Target to $14 From $7.50	22-12-21	MT
Morgan Stanley Adjusts Price Target on Adaptive Biotechnologies to $16 From $17, Maintains Equalweight Rating	22-11-07	MT
Piper Sandler Adjusts Price Target on Adaptive Biotechnologies to $7.50 From $12, Maintains Neutral Rating	22-10-26	MT
Credit Suisse Initiates Adaptive Biotechnologies at Underperform with $8 Price Target	22-08-25	MT
Credit Suisse Initiates Coverage of 20 Companies in Life Science Tools, Services, Diagnostics Sectors; Outperform-Rated Bio-Rad, IQVIA, Bipo-Techne, Natera Named Top Picks	22-08-25	MT
Piper Sandler Increases Price Target on Adaptive Biotechnologies to $12 From $7.50, Reiterates Neutral Rating	22-08-18	MT
BTIG Adjusts Price Target for Adaptive Biotechnologies to $17 From $25, Maintains Buy Rating	22-08-04	MT
Piper Sandler Starts Adaptive Biotechnologies at Neutral With $7.50 Price Target	22-06-03	MT
Goldman Sachs Adjusts Adaptive Biotechnologies' Price Target to $10 from $14, Keeps Neutral Rating	22-05-24	MT
Goldman Sachs Adjusts Adaptive Biotechnologies' Price Target to $21 from $54, Maintains Neutral Rating	22-02-16	MT
JPMorgan Adjusts Adaptive Biotechnologies' Price Target to $50 from $75, Maintains Overweight Rating	22-02-16	MT
BTIG Adjusts Adaptive Biotechnologies' Price Target to $30 from $35, Maintains Buy Rating	22-02-16	MT
Morgan Stanley Adjusts Adaptive Biotechnologies Price Target to $27 From $46, Maintains Equalweight Rating	22-02-15	MT
BTIG Adjusts Adaptive Biotechnologies' Price Target to $45 From $55; Buy Rating Kept	22-01-11	MT
ADAPTIVE BIOTECHNOLOGIES : Goldman Sachs Adjusts Price Target on Adaptive Biotechnologies to $52 From $59, Maintains Neutral Rating	21-08-06	MT
ADAPTIVE BIOTECHNOLOGIES : Morgan Stanley Adjusts Adaptive Biotechnologies PT to $55 From $60, Maintains Equal Weight Rating	21-05-07	MT
ADAPTIVE BIOTECHNOLOGIES : Goldman Sachs Downgrades Adaptive Biotechnologies to Neutral From Buy, Adjusts Price Target to $63 From $74	21-03-03	MT
ADAPTIVE BIOTECHNOLOGIES : Morgan Stanley Adjusts Price Target on Adaptive Biotechnologies to $60 From $46, Keeps Equal-Weight Rating	21-02-26	MT
ADAPTIVE BIOTECHNOLOGIES : BTIG Research Adjusts Adaptive Biotechnologies PT to $63 From $60, Maintains Buy Rating	20-11-12	MT